Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
irinotecan/neoplasms
Länken sparas på Urklipp
Sida 1 från 44 resultat
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Despite improvements in cancer treatments, there remains a critical need to further improve therapies so as to prolong patients' lives while maintaining quality of life, particularly in the case of advanced cancers such as pancreatic cancers that often are, or become, resistant to current
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Despite improvements in cancer treatments, there remains a critical need to further improve therapies so as to prolong patients' lives while maintaining quality of life, particularly in the case of advanced cancers such as pancreatic cancers that often are, or become, resistant to current
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Despite improvements in cancer treatments, there remains a critical need to further improve therapies so as to prolong patients' lives while maintaining quality of life, particularly in the case of advanced cancers such as pancreatic cancers that often are, or become, resistant to current
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
Despite improvements in cancer treatments, there remains a critical need to further improve therapies so as to prolong patients' lives while maintaining quality of life, particularly in the case of advanced cancers such as pancreatic cancers that often are, or become, resistant to current
Solid oral dosage form of irinotecan for the treatment of cancer
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
This present invention relates to a pharmaceutical composition comprising Irinotecan (or a pharmaceutically acceptable salt thereof) and intended for oral use for the treatment of cancer. Typically, the oral dosage form is a solid dosage form that has a high oral
Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention relates to antineoplastic agents and in particular to antineoplastic agents whose oral effectiveness is limited by pre-systemic and systemic deactivation. The present invention further relates to orally administered gastric delivery systems for releasing
Therapeutic use of new pharmaceutical preparations containing antitumoral drugs bound to hyaluronic acid in the treatment of neoplasias
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
This Application is the National Phase Under 35 U.S.C. .sctn.371 of PCT International Application No. PCT/IB2009/005309, which has an International filing, date of Apr. 21, 2009, and claims priority to two Italian patent applications. Italian Patent Application No. PD2008A 000125 filed on Apr. 22,
Methods of using thalidomide in combination with irinotecan
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. FIELD OF THE INVENTION
This invention relates to pharmaceutical compositions comprising thalidomide and irinotecan, to methods of treating colorectal cancer, and to methods of reducing or avoiding adverse effects of irinotecan.
2. BACKGROUND OF THE INVENTION
2.1. Colorectal Cancer
Cancer is
Liposomal formulation of irinotecan
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
This invention pertains to formulations and methods for making camptothecin-containing liposomes that minimize or reduce multidrug resistance when administered to humans. The invention is also directed to the use of these liposomes in the treatment of disease,
Method for determining sensitivity to irinotecan and use thereof
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
CROSS-REFERENCE TO RELATED APPLICATIONS
The present application is a 35 U.S.C. .sctn.371 National Stage patent application of International patent application PCT/JP2010/001772, filed on Mar. 12, 2010, which claims priority to Japanese patent application JP 2009-061455, filed on Mar. 13,
Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Patients diagnosed with cancer are faced with costly and often painful treatment options. These treatments may be ineffective in a subpopulation of patients, and as a result, these patients endure these treatments without little or no therapeutic benefit. Some patients
Gene and protein expression profiles associated with the therapeutic efficacy of irinotecan
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Patients diagnosed with cancer are faced with costly and often painful treatment options. These treatments may be ineffective in a subpopulation of patients, and as a result, these patients endure these treatments without little or no therapeutic benefit. Some patients
Compositions and methods for the treatment of colorectal cancer
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. FIELD OF THE INVENTION
This invention relates to pharmaceutical compositions comprising thalidomide and irinotecan, to methods of treating colorectal cancer, and to methods of reducing or avoiding adverse effects of irinotecan.
2. BACKGROUND OF THE INVENTION
2.1. Colorectal Cancer
Cancer is
Fixed ratio drug combination treatments for solid tumors
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TECHNICAL FIELD
The invention relates to methods for improved delivery and therapeutic effectiveness of a combination of therapeutic agents. More particularly, the inventions relates to delivery of a fixed ratio combination of floxuridine and irinotecan.
BACKGROUND ART
In vitro studies show that
Method of administering camptothecin compounds for the treatment of cancer with reduced side effects
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention relates to camptothecin compounds, in particular, irinotecan hydrochloride composition formulations, and methods of administering camptothecin compounds such as irinotecan hydrochloride for the treatment of cancer and AIDS, with reduced side
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
